Suppr超能文献

含钠对乙酰氨基酚与高血压或不高血压个体的心血管结局。

Sodium-containing acetaminophen and cardiovascular outcomes in individuals with and without hypertension.

机构信息

Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.

Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

Eur Heart J. 2022 May 7;43(18):1743-1755. doi: 10.1093/eurheartj/ehac059.

Abstract

AIMS

Previous studies have found high sodium intake to be associated with increased risks of cardiovascular disease (CVD) and all-cause mortality among individuals with hypertension; findings on the effect of intake among individuals without hypertension have been equivocal. We aimed to compare the risks of incident CVD and all-cause mortality among initiators of sodium-containing acetaminophen with the risk of initiators of non-sodium-containing formulations of the same drug according to the history of hypertension.

METHODS AND RESULTS

Using The Health Improvement Network, we conducted two cohort studies among individuals with and without hypertension. We examined the relation of sodium-containing acetaminophen to the risk of each outcome during 1-year follow-up using marginal structural models with an inverse probability weighting to adjust for time-varying confounders. The outcomes were incident CVD (myocardial infarction, stroke, and heart failure) and all-cause mortality. Among individuals with hypertension (mean age: 73.4 years), 122 CVDs occurred among 4532 initiators of sodium-containing acetaminophen (1-year risk: 5.6%) and 3051 among 146 866 non-sodium-containing acetaminophen initiators (1-year risk: 4.6%). The average weighted hazard ratio (HR) was 1.59 [95% confidence interval (CI) 1.32-1.92]. Among individuals without hypertension (mean age: 71.0 years), 105 CVDs occurred among 5351 initiators of sodium-containing acetaminophen (1-year risk: 4.4%) and 2079 among 141 948 non-sodium-containing acetaminophen initiators (1-year risk: 3.7%), with an average weighted HR of 1.45 (95% CI 1.18-1.79). Results of specific CVD outcomes and all-cause mortality were similar.

CONCLUSION

The initiation of sodium-containing acetaminophen was associated with increased risks of CVD and all-cause mortality among individuals with or without hypertension. Our findings suggest that individuals should avoid unnecessary excessive sodium intake through sodium-containing acetaminophen use.

摘要

目的

先前的研究发现,高血压患者的钠摄入量高与心血管疾病(CVD)和全因死亡率的增加有关;而对于没有高血压的患者,摄入的影响则存在争议。我们旨在根据高血压病史,比较含钠对乙酰氨基酚与同一种药物的不含钠配方的起始者发生 CVD 和全因死亡率的风险。

方法和结果

我们利用健康改善网络(Health Improvement Network),在有和没有高血压的患者中进行了两项队列研究。我们使用边际结构模型和逆概率加权来调整随时间变化的混杂因素,在 1 年的随访中,检查了含钠对乙酰氨基酚与每种结果之间的关系。结果是 CVD 事件(心肌梗死、中风和心力衰竭)和全因死亡率。在有高血压的患者中(平均年龄:73.4 岁),4532 名含钠对乙酰氨基酚起始者中有 122 例发生 CVD(1 年风险:5.6%),146866 名不含钠对乙酰氨基酚起始者中有 3051 例发生 CVD(1 年风险:4.6%)。平均加权风险比(HR)为 1.59[95%置信区间(CI)1.32-1.92]。在没有高血压的患者中(平均年龄:71.0 岁),5351 名含钠对乙酰氨基酚起始者中有 105 例发生 CVD(1 年风险:4.4%),141948 名不含钠对乙酰氨基酚起始者中有 2079 例发生 CVD(1 年风险:3.7%),平均加权 HR 为 1.45(95%CI 1.18-1.79)。特定 CVD 结果和全因死亡率的结果相似。

结论

含钠对乙酰氨基酚的起始与有或没有高血压的患者 CVD 和全因死亡率的增加有关。我们的研究结果表明,个体应避免通过使用含钠对乙酰氨基酚摄入不必要的过量钠。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e06/9076395/e2ffb704ef6b/ehac059ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验